278 related articles for article (PubMed ID: 1386634)
1. Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy.
Reeve PA; Ala J; Hall JJ
J Trop Med Hyg; 1992 Aug; 95(4):266-70. PubMed ID: 1386634
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
5. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
6. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
[TBL] [Abstract][Full Text] [Related]
7. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy.
Pattyn SR; Janssens L; Bourland J; Saylan T; Davies EM; Grillone S; Feracci C
Int J Lepr Other Mycobact Dis; 1984 Mar; 52(1):1-6. PubMed ID: 6368424
[TBL] [Abstract][Full Text] [Related]
10. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
[TBL] [Abstract][Full Text] [Related]
11. Multi-drug therapy in bacilliferous leprosy--two years experience.
Kaur S; Sharma VK; Kumar B; Singh M; Kaur I
Indian J Lepr; 1985; 57(3):483-90. PubMed ID: 3831085
[TBL] [Abstract][Full Text] [Related]
12. Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria.
Pieters FA; Woonink F; Zuidema J
Eur J Clin Pharmacol; 1988; 34(1):73-6. PubMed ID: 3360051
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
14. Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy--a five year retrospective study.
Kaluarachchi SI; Fernandopulle BM; Gunawardane BP
Indian J Lepr; 2001; 73(2):121-9. PubMed ID: 11579648
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Lim JT; Tan T
Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
[TBL] [Abstract][Full Text] [Related]
16. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
Chandorkar AG; Burte NP; Gade RK; Bulakh PM
Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
[TBL] [Abstract][Full Text] [Related]
17. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
[TBL] [Abstract][Full Text] [Related]
18. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
19. Dapsone syndrome--a case report.
Khare AK; Bansal NK; Meena HS
Indian J Lepr; 1987; 59(1):106-9. PubMed ID: 3611856
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and hematological side effects of clofazimine in leprosy patients.
Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
